| Cat.No. | Name | Information |
|---|---|---|
| M8915 | Dubermatinib | Dubermatinib (TP-0903) is a potent and selective AXL inhibitor with an IC50 value of 27 nM. |
| M2023 | Bemcentinib | R428 is a potent and selective small-molecule inhibitor of Axl kinase with IC50 of 14 nM. |
| M21696 | Batiraxcept | Batiraxcept (AVB-S6-500) is a highly potent and specific AXL inhibitor, a recombinant fusion protein dimer containing the extracellular domain of human AXLM and human immunoglobulin G1 heavy chain (Fc). Batiraxcept binds to GAS6 and inhibits the interaction of GAS6 with AXL, thereby substantially reducing AXL signaled invasion and migration of highly metastatic cells in vitro. |
| M11240 | XL092 | XL092 is an orally active, ATP-competitive inhibitor of multireceptor tyrosine kinases (RTKs), including MET, VEGFR2, AXL and MER, with IC50 values of 15 nM, 1.6 nM, 3.4 nM and 7.2 nM in cell analysis, respectively. XL092 has antitumor activity. |
| M11238 | UNC569 | UNC569 is a potent, reversible, ATP-competitive and orally active Mer kinase inhibitor with IC50 of 2.9 nM and Ki of 4.3 nM. UNC569 also inhibited Axl and Tyro3 with IC50 of 37 nM and 48 nM, respectively. |
| M11231 | LDC1267 | LDC1267 is a highly selective inhibitor of TAM (Tyro3,Axl and Mer) kinases with IC50 values of <5 nM/8 nM/29 nM against Tyro3/Axl/Mer, respectively. |
| M10497 | ONO-7475 | ONO-7475 is a potent and orally active Axl/Mer inhibitor with IC50 values of 0.7 nM and 1.0 nM, respectively. |
| M9385 | RU-301 | RU-301 is a pan-TAM receptor inhibitor that blocks Gas6-induced TAM activation and tumorigenicity, with Kd and IC50 values of 12 μM and 10 μM, respectively. |
| M4875 | UNC2881 | UNC2881 is a specific Mer tyrosine kinase inhibitor with IC50 of 4.3 nM, about 83- and 58-fold selectivity over Axl and Tyro3, respectively |
| M3108 | UNC2250 | UNC2250 is a potent and selective Mer inhibitor with IC50 of 1.7 nM, about 160- and 60-fold selectivity over the closely related kinases Axl/Tyro3. |
| M2180 | SGI-7079 | SGI-7079 is a novel Axl inhibitor. |
| M30936 | Glesatinib | Glesatinib (MGCD265) is an orally active, potent MET/SMO dual inhibitor. Glesatinib, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC). |
| M28955 | DS-1205b free base | DS-1205b free base is a potent and selective inhibitor of AXL kinase, with an IC50 of 1.3 nM. DS-1205b free base also inhibits MER, MET, and TRKA, with IC50s of 63, 104, and 407 nM, respectively. DS-1205b free base can inhibit cell migration in vitro and tumor growth in vivo. |
| M28324 | Ningetinib Tosylate | Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively. |
| M27894 | RU-302 | RU-302 is a pan TAM inhibitor that blocks the interface between the TAM Ig1 ectodomain and the Gas6 Lg domain. RU-302 effectively blocks Gas6-inducible Axl receptor activation with a low micromolar IC50in cell assays, and suppresses lung cancer tumor growth. |
| M25072 | Mipasetamab uzoptirine | Mipasetamab uzoptirine (ADCT-601) is an AXL-targeted antibody-drug conjugates (ADCs). Mipasetamab uzoptirine consists of a humanized anti-AXL antibody, a cleavable linker and the potent pyrrolobenzodiazepine (PBD) dimer cytotoxin SG3199. Mipasetamab uzoptirine can be used for the research of cancers. |
| M25009 | Tilvestamab | Tilvestamab (BGB149) is a humanized anti-AXL antibody that blocks AXL-mediated cell signaling. Tilvestamab significantly inhibits Gas6-induced AXL activation in 786-0-Luc RCC cells and inhibits downstream AKT phosphorylation. Tilvestamab can be used in cancer research, particularly in AXL overexpressing renal cell carcinomas. |
| M24848 | Enapotamab | Enapotamab is an anti-AXL/UFO reference antibody. Enapotamab can be used to synthesis Bcl-xl inhibitor antibody-drug conjugates. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
